ReviewNeuroSci2022
Cognitive Impairment in Multiple Sclerosis: An Update on Assessment and Management.
Review in NeuroSci, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Comparing cognitive impairment using MACFIMS in patients with multiple sclerosis and healthy controls: a systematic review and meta-analysis.BMC neurology · 2024Pooled it
- Sleep and cognitive outcomes in multiple sclerosis; a systematic review.BMC psychiatry · 2024Pooled it
- The Effects of Coffee/Caffeine in Patients with Multiple Sclerosis; A Systematic Review.Journal of evidence-based integrative medicinePooled it
- Dietary regimens and cognitive function in multiple sclerosis: a systematic review.Brain, behavior, & immunity - health · 2026Review
- Multi-compartment Myelin Streamline Decomposition reveals tract-specific and global brain network myelination in Multiple Sclerosis.Neuroimage. Reports · 2026Article
- Frequent early cognitive impairment in both pediatric MS and MOGAD.Multiple sclerosis (Houndmills, Basingstoke, England) · 2026Article
- Rethinking prognosis in multiple sclerosis: a multiaxial perspective.Nature reviews. Neurology · 2026Review
- MicroRNA-mRNA Regulatory Network Associated with Cognitive Impairment in Multiple Sclerosis.Molecular neurobiology · 2026Article
- Salivary cortisol as a neuroendocrine stress biomarker for xerostomia in multiple sclerosis patients: a comparative cross-sectional study.BMC oral health · 2026Article
- Justice, Disability, and Law: A Neurological and Ethical Assessment of Multiple Sclerosis in Turkey.BMC medical ethics · 2026Article
- Volumetric MRI Markers of Cognitive Impairment in Relapsing-Remitting Multiple Sclerosis: Cerebellar White Matter Loss, Pallidum Atrophy, and Choroid Plexus Enlargement.Brain sciences · 2026Article
- Exploring the Link Between IL-6 rs1800795 G > C SNP and the Severity of Epstein-Barr Virus-Associated Multiple Sclerosis: Potential Impact on Cognitive Impairment.Molecular neurobiology · 2025Article
- Navigating a Misty Road: Novel Ways to Study the Impact of Cognition on Driving Performance in Multiple Sclerosis.Brain sciences · 2025Review
- Brain Atrophy and Cognitive Impairment in Primary and Secondary Progressive Multiple Sclerosis Cohort-Similar Progressive MS Phenotype.International journal of molecular sciences · 2025Article
- Sensitivity and Specificity of a Revised Version of the TRACK-MS Screening Battery for Early Detection of Cognitive Impairment in Patients with Multiple Sclerosis.Biomedicines · 2025Article
- Article
- Cognitive Functioning in Toxic Oil Syndrome Survivors: A Case-Control Study Four Decades After the Epidemic.Journal of clinical medicine · 2025Article
- Correlates of Inaccuracy in Reporting of Energy Intake Among Persons with Multiple Sclerosis.Nutrients · 2025Article
- Correlation of Cognition With Disability and Physical Performance in Patients With Relapsing-Remitting MS.Journal of central nervous system disease · 2025Article
- Predicting multiple sclerosis disease progression and outcomes with machine learning and MRI-based biomarkers: a review.Journal of neurology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cognitive impairment (CI) is a core feature of multiple sclerosis (MS) and affects up to 65% of patients in every phase of the disease, having a deep impact on all aspects of patients' lives. Cognitive functions most frequently involved include information processing speed, learning and memory, visuospatial abilities, and executive function. The precise pathogenetic mechanisms underpinning CI in MS are still largely unknown, but are deemed to be mainly related to pathological changes in lesioned and normal-appearing white matter, specific neuronal grey matter structures, and immunological alterations, with particular impact on synaptic transmission and plasticity. Moreover, much research is needed on therapeutic strategies. Small to moderate efficacy has been reported for disease-modifying therapies, particularly high-efficacy drugs, and symptomatic therapies (dalfampridine), while the strongest benefit emerged after cognitive training. The present narrative review provides a concise, updated overview of more recent evidence on the prevalence, profile, pathogenetic mechanisms, and treatment of CI in people with MS. CI should be screened on a regular basis as part of routine clinical assessments, and brief tools are now widely available (such as the Symbol Digit Modalities Test). The main goal of cognitive assessment in MS is the prompt implementation of preventive and treatment interventions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.